Evidence map›Paper›PMID 28848819›Full record

ReviewChronic obstructive pulmonary diseases (Miami, Fla.)2014

Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns.

Alvar Agustí, Peter M Calverley, Marc Decramer, Robert A Stockley, Jadwiga A Wedzicha

Open access · bronzeAbstract readReview
In one paragraph

Review in Chronic obstructive pulmonary diseases (Miami, Fla.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study.International journal of chronic obstructive pulmonary disease · 2021
    Trial
  3. Article
  4. Review
  5. Review
  6. Giving Voice to People - Experiences During Mild to Moderate Acute Exacerbations of COPD.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2022
    Article
  7. Article
  8. OscillococcinumDrugs in context · 2021
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.International journal of chronic obstructive pulmonary disease · 2016
    Observational
  15. Treatable Traits in COPD - A Proposed Approach.International journal of chronic obstructive pulmonary disease
    Review
  16. Article
  17. Review
  18. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Alvar AgustíInstitut del Tòrax, Hospital Clínic, Barcelona, Spain.
Peter M CalverleyClinical Sciences Center, University Hospital Aintree, Liverpool, United Kingdom.
Marc DecramerRespiratory Division, University Hospitals, Leuven, Belgium.
Robert A StockleyLung Investigation Unit, University Hospitals of Birmingham, Edgbaston, Birmingham, United Kingdom.
Jadwiga A WedzichaAirways Disease Section, National Heart and Lung Institute, Imperial College London, United Kingdom.
Aintree University Hospital · GBImperial College London · GBKU Leuven · BEThe Edgbaston Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2011 recommendations of the Global initiative for chronic Obstructive Lung Disease (GOLD) constituted a major paradigm shift in COPD management since they set 2 major goals for the assessment and management of patients:

Indexed as

chronic bronchitiscopdemphysemaexacerbationsinflammationsmokingtherapy

Identifiers

PMID28848819
PMCPMC5556862
OpenAlexW2323544223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.